GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aurobindo Pharma Ltd (BOM:524804) » Definitions » Cash Ratio

Aurobindo Pharma (BOM:524804) Cash Ratio : 0.52 (As of Sep. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Aurobindo Pharma Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Aurobindo Pharma's Cash Ratio for the quarter that ended in Sep. 2024 was 0.52.

Aurobindo Pharma has a Cash Ratio of 0.52. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Aurobindo Pharma's Cash Ratio or its related term are showing as below:

BOM:524804' s Cash Ratio Range Over the Past 10 Years
Min: 0.08   Med: 0.27   Max: 0.64
Current: 0.52

During the past 13 years, Aurobindo Pharma's highest Cash Ratio was 0.64. The lowest was 0.08. And the median was 0.27.

BOM:524804's Cash Ratio is ranked worse than
52.64% of 1005 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs BOM:524804: 0.52

Aurobindo Pharma Cash Ratio Historical Data

The historical data trend for Aurobindo Pharma's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurobindo Pharma Cash Ratio Chart

Aurobindo Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.25 0.53 0.56 0.54 0.52

Aurobindo Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 - 0.52 - 0.52

Competitive Comparison of Aurobindo Pharma's Cash Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurobindo Pharma's Cash Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Aurobindo Pharma's Cash Ratio falls into.



Aurobindo Pharma Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Aurobindo Pharma's Cash Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

Cash Ratio (A: Mar. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=63251.7/121991.3
=0.52

Aurobindo Pharma's Cash Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash Ratio (Q: Sep. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=75225.6/143405.8
=0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aurobindo Pharma  (BOM:524804) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Aurobindo Pharma Cash Ratio Related Terms

Thank you for viewing the detailed overview of Aurobindo Pharma's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurobindo Pharma Business Description

Traded in Other Exchanges
Address
Plot No. 1, Survey No. 83/1, Galaxy, Floors 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500032
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.

Aurobindo Pharma Headlines

No Headlines